VGI Health Technology Limited

Equities

VTL

AU0000152597

Biotechnology & Medical Research

End-of-day quote National Stock Exchange of Australia Other stock markets 06:00:00 2023-06-28 pm EDT			5-day change	1st Jan Change
0.02 ^AUD	-33.33%		-.--%	-.--%

Feb. 08	VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
2023	VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

VGI Health Technology : NE1-Elite® and NE1-Heart® nutraceutical products listed on Amazon

January 19, 2022 at 05:46 pm EST

VGI Health Technology Limited

ABN: 35 111 082 485

Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000

www.vgiht.com | Tel: +61 2 8279 8908

VGI Health Technology's NE1-Elite® and NE1-Heart® nutraceutical products listed on Amazon

Sydney New South Wales, 20 January 2022 - Invictus Nutraceuticals, Inc. (Florida, USA), a wholly owned subsidiary of VGI Health Technology Limited (NSX:VTL), is pleased to announce that both NE1-Elite® and NE1-Heart® are now available for sale on Amazon in the United States.

Amazon invests billions of dollars each year in logistics, tools, services and programs to help sellers build their brand. Invictus Nutraceuticals develops and commercializes nutraceutical products based on two proprietary and patented delivery platforms for improving the bioavailability and efficacy of tocotrienols (a natural product which is one part of vitamin E).

NE1-Elite® reduces Delayed Onset Muscle Soreness (DOMS) and improves muscle recovery after workout along with being Informed Sport Certified (banned substance free tested).

NE1-Heart® maintains heart health and increases the antioxidant status in the body.

Richard Estalella, the President and CEO of Invictus Nutraceuticals, Inc. said "We are delighted to have Amazon be the foundation of our national online selling business. Being able to leverage Amazon's scale to reach more customers is very exciting and this is a major milestone for the commercialisation of our nutraceutical products."

Invictus Nutraceuticals, Inc. will initiate marketing and promotional programs on the Amazon platform in the near future.

VGI Health Technology Limited

For more information please contact:
Glenn Tong, CEO and Managing Director	Catriona Glover, Company Secretary
Ph: +61 (0) 412 193 350	Tel: +61 (0) 402 328 200
Andrew Crook, Investor and Media Relations
Ph:+61 (0) 419 788 431

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed biotechnology company (NSX:VTL) developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: https://www.vgiht.com

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp

Attachments

Original Link
Original Document
Permalink

Disclaimer

VGI Health Technology Ltd. published this content on 20 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 January 2022 22:45:08 UTC.

Latest news about VGI Health Technology Limited

VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 08	CI
VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-06	CI
Certain Ordinary Shares of VGI Health Technology Limited are subject to a Lock-Up Agreement Ending on 28-MAY-2023.	23-05-27	CI
VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-15	CI
VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-09	CI
VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt	22-08-09	CI
Certain Ordinary Shares of VGI Health Technology Limited are subject to a Lock-Up Agreement Ending on 28-MAY-2022.	22-05-27	CI
ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study	21-11-29	CI
VGI Health Technology Hires Darrell Crawford to Scientific Advisory Board	21-09-14	CI
Vgi Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-07	CI
Moko Social Media Limited Announces Resignations of Non-Executive Directors	16-04-17	CI
Moko Social Media Limited(ASX:MKB) dropped from S&P/ASX Emerging Companies Index	16-03-21	CI
Moko Social Media Limited Reports Unaudited Consolidated Earnings Results for the Half Year Ended 31 December 2015	16-03-01	CI
MOKO Social Media Announces Management Changes	16-02-18	CI
True Blue Media, LLC, acquired Blue Nation Review from Moko Social Media Limited.	15-11-24	CI
Moko Social Media Limited Announces Retirement of Jeff White as Director	15-11-17	CI
Moko Social Media Limited Announces Consolidated Cash Flow Results for the First Quarter Ended September 30, 2015	15-10-30	CI
Moko Social Media Limited Announces Audited Consolidated Earnings Results for the Year Ended June 30, 2015	15-10-04	CI
Moko Social Media Limited Reports Parent Earnings Results for the Year Ended 30 June 2015	15-09-30	CI
VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt	15-09-29	CI
Moko Social Media Limited Appoints Diana Rhoten as Non-Executive Director with Effect from 1 October 2015	15-09-23	CI
MOKO Social Media Appoints Emma Waldon as Non-Executive Director with Effect from 1 October 2015	15-09-22	CI
Moko Social Media Limited Reports Unaudited Preliminary Consolidated Earnings Results for the Year Ended 30 June 2015	15-08-30	CI
MOKO Social Media Limited completed the acquisition of 10% stake in BigTeams, LLC for $1 million.	15-04-27	CI
Moko Social Media Limited Announces Resignation of Hans de Back, Non Executive Director	15-04-12	CI

Chart VGI Health Technology Limited

Duration

Period

More charts

Company Profile

VGI Health Technology Limited is an Australia-based biotechnology company. The Companyâs MELT3 formulation of Tocotrienols (T3s) is designed to be dissolved in the mouth and then swallowed, which is used for certain non-disease and self-limiting exercise related indications, such as reduction of delayed onset muscle soreness (DOMS), improved muscle recovery after exercise and improved maintenance of muscle power. MELT3 is designed for nutraceuticals and dietary supplements. Its TransT3, a transmucosal delivery platform for T3s, is designed to enhance absorption of the T3s by facilitating sublingual and buccal (transmucosal) absorption. T3s are absorbed into the capillaries below the sublingual and buccal mucosa and then released into the blood stream. Its Tocotrienol ProDrugs (TPD) is a prodrug delivery platform for T3s designed to enhance absorption of T3s into the lymphatic system of the gut and release of T3s into the blood stream.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VGI HEALTH TECHNOLOGY LIMITED	-.--%	1.78M
VERTEX PHARMACEUTICALS INCORPORATED	-3.30%	102B
REGENERON PHARMACEUTICALS, INC.	+1.79%	96.07B
ARGENX SE	-0.44%	21.66B
BIONTECH SE	-18.35%	20.77B
GENMAB A/S	-7.45%	18.53B
WUXI APPTEC CO., LTD.	-40.31%	16.91B
BEIGENE, LTD.	-26.84%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.59%	13.33B
SAREPTA THERAPEUTICS, INC.	+20.86%	10.94B

Bio Therapeutic Drugs